VCM
BRTX icon

Vanguard Capital Management’s BioRestorative Therapies BRTX Stock Holding History

Vanguard Capital Management’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.88K Buy
+12,977
New +$3.8K ﹤0.01% 4069

Other funds holding BRTX

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's BRTX Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in BioRestorative Therapies (BRTX) in Q2 2026: 12,977 shares worth $4.88K. The stake represents ﹤0.01% of the portfolio and ranks #4069 among its holdings.

15 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • Vanguard Capital Management held 12,977 shares of BioRestorative Therapies worth $4.88K as of Q2 2026.
  • BioRestorative Therapies was a new Vanguard Capital Management position in Q2 2026.
  • BioRestorative Therapies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4069 holding.
  • 15 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.